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Pirfenidone is an antifibrotic agent that has been proven to slow down the progression of idiopathic 
pulmonary fibrosis (IPF). The aim of this study was to evaluate the efficacy of low-dose pirfenidone 
(that is, less than 1200 mg/day). We retrospectively reviewed the medical records of patients with 
IPF. The patients were divided into the following three groups, those who were not treated with 
pirfenidone (control) and those who were treated with pirfenidone at doses < 1200 mg/day (low-dose 
group) and ≥ 1200 mg/day (high-dose group). The adjusted mean changes in forced vital capacity (FVC) 
in 1 year were − 200.7, − 88.4, and − 94.7 mL in the control, low-dose, and high-dose groups (p = 0.021). 
The FVC declined more significantly in the control group than in the low-dose and high-dose groups. 
No significant difference in FVC change was observed between the low-dose and high-dose groups. 
Dyspepsia, anorexia, and nausea were significantly more frequent in the low-dose than in the high-
dose group, suggesting that dose reduction is attributed to gastrointestinal tract-related adverse 
events. Dose reduction may help patients to better control gastrointestinal tract-related adverse 
events; continuing taking the medication at low doses is also expected to be effective in reducing the 
FVC decline.
Abbreviations
AE  Adverse event
AE-IPF  Acute exacerbation of IPF
BMI  Body mass index
BSA  Body surface area
DLCO  Diffusing capacity of the lungs for carbon monoxide
FEV1  Forced expiratory volume in one second %
FVC  Forced vital capacity
GAP  Gender–age–physiology
GI  Gastrointestinal
IPF  Idiopathic pulmonary fibrosis
IQR  Interquartile range
Idiopathic pulmonary fibrosis (IPF), a chronic, progressive, fibrotic interstitial lung disease of unknown cause, is 
characterized by irreversible loss of lung function due to lung scarring, typically occurring in individuals older 
than 60 years1,2. Although the clinical course is highly variable, progressive decline in pulmonary function until 
eventual death from respiratory failure or complicating comorbidity is inevitable, and median survival is known 
to be approximately 3 years3,4. Despite a poor outcome and devastating respiratory symptoms, no effective thera-
peutic approach for improving survival besides lung transplantation was available until the emergence of two 
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novel drugs, pirfenidone and nintedanib, which were approved by the Korean Food and Drug Administration 
in 2012 and 2016, respectively.
Pirfenidone has been proven to slow down forced vital capacity (FVC) decline and reduce the risk of death 
by 48% at 1 year in a pooled analysis of data from three independent  cohorts5. Furthermore, it lowered the risk 
of respiratory-related hospitalization over the course of 1 year6. Pirfenidone at a dose of 40 mg/kg/day was tested 
in a phase II clinical  trial7. A phase III clinical trial in a Japanese cohort was designed to test 1800 mg/day pir-
fenidone, which was lower than that administered in the phase II clinical  trial8, and 2403 mg/day in the United 
States, Europe, Australia, and North  America9,10. Finally, pirfenidone was approved with the full recommended 
dose of 1800 mg/day in Korea and Japan and 2403 mg/day in Europe and the United States. However, in real 
clinical practice, considerable number of patients take reduced doses, rather than the recommended dose, due 
to adverse drug  reactions11,12. A Japanese study, involving all-case post-marketing surveillance of 1371 patients 
treated with pirfenidone, reported that the most frequent daily dose was less than 1200 mg/day in approximately 
60% of  patients13.
A Japanese phase III clinical trial evaluated high-dose pirfenidone (1800 mg/day), low-dose (1200 mg/day), 
and placebo and reported that the low-dose group showed a significant effect on disease progression assessed 
by FVC decline compared with the placebo  group8. However, the effects of pirfenidone less than 1200 mg/day 
dose have not been confirmed.
Therefore, the present study aimed to determine the proportion of patients taking low-dose pirfenidone (less 
than 1200 mg) and evaluate the efficacy of low-dose pirfenidone on disease progression based on FVC change.
Results
Patient characteristics. In total, 234 patients with IPF, with 92 patients not treated with pirfenidone (con-
trol group) and 142 patients treated with pirfenidone, were enrolled. The median follow-up period of total study 
population was 25.6 (interquartile range [IQR], 14.1–34.5) months. The median age was 69.0 (IQR, 64.0–74.8) 
years, and 74.4% patients were men. Patients treated with pirfenidone were divided into the following two 
groups: those taking less than 1200 mg/day (low-dose group) and those taking 1200 mg/day or more (high-dose 
group). The baseline characteristics of the study population are shown in Table 1. The median age was higher 
in the low-dose group than in the control and high-dose groups (68.0 vs. 72.0 vs. 67.0, control vs. low-dose vs. 
high-dose group in order, p = 0.001). The proportion of male (69.4% vs. 69.6% vs. 87.3%, control vs. low-dose 
vs. high-dose group in order, p = 0.023) and body mass index (BMI; 23.3 ± 3.0 vs. 24.3 ± 3.0 vs. 25.4 ± 2.7, control 
vs. low-dose vs. high-dose group in order, p < 0.001) were higher in the high-dose group than in the control 
and low-dose groups. Predicted FVC % (83.6 ± 20.0 vs. 77.6 ± 12.9 vs. 76.3 ± 13.1, control vs. low-dose vs. high-
dose group in order, p = 0.004) and predicted forced expiratory volume in one second %  (FEV1; 96.2 ± 22.6 vs. 
93.3 ± 16.1 vs. 87.6 ± 12.9, control vs. low-dose vs. high-dose group in order, p = 0.005) were higher in the control 
group than in the other two groups, whereas the actual measured values of FVC and  FEV1 were not different 
among the groups. The severity of IPF assessed using the GAP index also did not show a significant difference 
among the groups.
Medication dose distribution. The distribution of pirfenidone dose per day is shown in Fig.  1a. The 
median of pirfenidone dose was 1185 (IQR, 847–1456) mg. As shown in Table 1, patients in the high-dose group 
were younger and with higher BMI and BSA. To confirm the correlation among age, BMI, BSA, and medication 
dose, Pearson’s correlation test was performed. Age and medication dose showed a significant negative correla-
tion (σ = − 0.302, p < 0.001, Fig. 1b). BMI, BSA, and medication dose showed a significant positive correlation 
(σ = 0.201, p = 0.017, Fig. 1c; σ = 0.3591, p < 0.001, Fig. 1d, respectively). This finding suggests that patients with 
younger age, and higher BMI and BSA tolerated higher medication dose.
Treatment effect. As sex, age, height, and weight, which can affect the FVC value, were different among 
the groups, we adjusted these four variables and evaluated the changes in the FVC value among the groups. 
The adjusted mean changes in FVC in the first year were − 200.7 ± 28.2, − 88.4 ± 31.4, and − 94.7 ± 35.3 mL in 
the control, low-dose, and high-dose groups, respectively. Overall, the FVC change among the groups showed 
a significant difference (p = 0.021, Fig. 2). The FVC declined more significantly in the control group than in the 
high-dose group, with an adjusted mean FVC change difference of 106.0 ± 45.2 mL (p = 0.047). The FVC also 
declined more significantly in the control group than in the low-dose group, with an adjusted mean FVC change 
difference of 112.4 ± 42.2 mL (p = 0.026). There was no significant difference in the FVC change between the 
low-dose and high-dose groups (p = 0.976). The adjusted mean FVC changes among the groups are shown in 
Fig. 2. The FVC change in the second year was − 76.6 ± 10.8 and − 63.5 ± 44.8 mL in the low-dose and high-dose 
groups, respectively, indicating that the effect of low-dose pirfenidone persisted in the second year (Supplemen-
tary Fig. 1).
BSA-adjusted pirfenidone dosing. BSA-adjusted pirfenidone dose distribution is shown in Supplemen-
tary Fig. 2. The BSA-adjusted pirfenidone dose was normally distributed based on the mean 665.0 ± 201.8 mg/m2 
(Shapiro–Wilk normality test = 0.108, Supplementary Fig. 2). When the difference in FVC decline was evaluated 
by BSA-adjusted pirfenidone dose based on the mean value, the low (< 665.0 mg/m2) and high BSA-adjusted 
pirfenidone groups (≥ 665.0 mg/m2) did not show significant difference in FVC change. In contrast, the low 
and high BSA-adjusted pirfenidone groups showed a decreasing trend in FVC change compared with the con-
trol group, although the difference was not statistically significant (p = 0.051). The adjusted mean FVC changes 
among the groups according to BSA-adjusted pirfenidone dose are shown in Supplementary Fig. 2b. The results 
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suggest that even when the pirfenidone dose is adjusted by BSA, the low-dose group has the same effect as the 
high-dose group in reducing FVC decline compared with the control group.
Adverse events. The AEs that occurred during the study period in the pirfenidone treatment group are 
shown in Table 2. In 142 patients who were treated with pirfenidone, the majority of AEs were related to the GI 
tract or skin. The most frequent AEs were dyspepsia (38.7%), anorexia (25.4%), and rash (25.4%). Elevations in 
the level of alanine or aspartate aminotransferase (values that were three or more times the upper limit of the 
normal range) were observed in 8 (5.6%) patients. A comparison the frequency of AEs according to the dose 
revealed that dyspepsia (48.1% vs. 27.0%, p = 0.017), anorexia (35.4% vs. 12.7%, p = 0.004), and nausea (17.7% 
vs. 1.6%, p = 0.005) were significantly more frequent in the low-dose group than in the high-dose group. Skin-
related adverse events did not show a difference between the low-dose and high-dose groups. These findings 
suggest that dose reduction is mainly attributed to GI tract-related AEs. Furthermore, the fact that patients with 
younger age and higher BMI and BSA showed more tolerance to higher medication doses suggests that they 
could be more tolerable to GI tract-related AEs.
Acute exacerbation. Among the 234 patients with IPF, 36 patients experienced acute exacerbation during 
the study period. Furthermore, 10 (10.9%), 11 (14.1%), and 15 (23.8%) patients experienced acute exacerbation 
in the control, low-dose, and high-dose groups, respectively. No statistically significant difference was observed 
among the groups.
Table 1.  Baseline characteristics according to pirfenidone dose. Values are expressed as the mean ± standard 
deviation, number (%) or mean (interquartile range). BMI body mass index, COPD chronic obstructive 
pulmonary disease, DLCO diffusing capacity of the lungs for carbon monoxide, FEV1 forced expiratory volume 
in one second, FVC forced vital capacity, GAP gender, age, and physiology, GERD gastroesophageal reflux 
disease, IPF idiopathic pulmonary fibrosis, IQR interquartile range.
Control (n = 92) Low-dose (n = 79) High-dose (n = 63) P value
Sex (male) 64 (69.4%) 55 (69.6%) 55 (87.3%) 0.023
Age (year), IQR 68.0 (62.5–73.0) 72.0 (66.5–76.0) 67.0 (63.0–73.5) 0.001
BMI (kg/m2) 23.3 ± 3.0 24.3 ± 3.0 25.4 ± 2.7 < 0.001
Height (cm) 162.8 ± 7.5 162.1 ± 7.5 165.7 ± 6.1 0.008
Weight (kg) 62.0 ± 10.2 64.2 ± 10.4 69.7 ± 8.7 < 0.001
Smoking exposure (%) < 0.001
Never 7 (7.6%) 30 (38.0%) 13 (20.6%)
Former 51 (55.4%) 35 (44.3%) 45 (71.4%)
Current 34 (37.0%) 14 (17.7%) 5 (7.9%)
Smoking (pack-years), IQR 15.0 (0.0–32.5) 20.0 (0.0–40.0) 20.0 (10.0–40.0)
Comorbidity
Diabetes mellitus 24 (26.1%) 26 (32.9%) 12 (19.0%) 0.176
COPD 7 (7.6%) 7 (8.9%) 10 (15.9%) 0.220
GERD 27 (29.3%) 27 (34.2%) 19 (30.2%) 0.777
Asthma 5 (5.4%) 5 (6.3%) 6 (9.5%) 0.598
Old pulmonary tuberculosis 18 (19.6%) 15 (19.0%) 13 (20.6%) 0.970
Cancer 23 (25.0%) 15 (19.0%) 14 (22.2%) 0.641
Coronary artery disease 19 (20.9%) 12 (15.2%) 13 (20.6%) 0.587
Cerebrovascular disease 5 (5.4%) 2 (2.5%) 2 (3.2%) 0.585
Pulmonary function test (at IPF diagnosis)
FVC (L) 2.8 ± 0.9 2.5 ± 0.7 2.8 ± 0.6 0.582
FVC % pred 83.6 ± 20.0 77.6 ± 12.9 76.3 ± 13.1 0.004
FEV1 (L) 2.2 ± 0.7 2.0 ± 0.5 2.2 ± 0.4 0.586
FEV1% pred 96.2 ± 22.6 93.3 ± 16.1 87.6 ± 12.9 0.005
DLCO (mL/mmHg/min) 13.0 ± 4.6 10.3 ± 3.5 12.0 ± 3.3 0.126
DLCO % pred 69.8 ± 25.5 62.8 ± 16.4 65.0 ± 15.1 0.103
Severity of IPF (GAP stage) 0.230
I 68 (73.9%) 50 (63.3%) 43 (68.3%)
II 21 (22.8%) 28 (35.4%) 20 (31.7%)
III 3 (3.3%) 1 (1.3%) 0 (0.0%)
Follow-up period (months), IQR 31.1 (12.6–54.8) 24.4 (14.2–32.7) 24.1 (15.2–31.2) 0.072
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Discussion
Here, we evaluated the efficacy of low-dose pirfenidone (< 1200 mg/day) on disease progression based on FVC 
change and found that both low-dose and high-dose groups have similar efficacy in FVC decline compared with 
the control group. Dose reduction of pirfenidone is mainly attributable to GI tract-related AEs, and patients with 
younger age and higher BMI and BSA were treated with higher doses.
Although pirfenidone is reported to be a safe and tolerable  drug14, a considerable number of patients dis-
continue or reduce the medication dose due to AEs. Adverse event-related discontinuation has been reported 
to be 14.4–15.0% in clinical trials and 15.3–24.3% in actual clinical  practice11–13,15. Regarding dose reduction, a 
Japanese post marketing surveillance of pirfenidone reported that 61.8% patients received less than 1200 mg/day 
pirfenidone most frequently during the treatment period, although the approved dose is 1800 mg/day, which is 
lower than that in the United States and European  countries13. A pooled analysis of three pivotal phase III trials, 
CAPACITY (Study 004 and Study 006)9 and ASCEND (Study 016)10 trials, which evaluated pirfenidone in IPF 
patients, revealed that, among 623 patients who were intended to treat with pirfenidone 2403 mg/day, 59.7% 
patients had temporary dose reduction and 31.5% had permanent dose  reduction16. Despite discontinuation 
and dose modification in such a large proportion of patients, it is not clear whether the efficacy in these patients 
is similar to that in patients taking full doses.
In a pooled analysis of phase III trials, to evaluate changes in efficacy following dose modification, the patients 
were divided based on dose intensity > 90% and ≤ 90%. The study reported that both groups of patients showed a 
significantly smaller decrease in the annual rate of FVC decline than the placebo  group16. In the study, the dose 
intensity cutoff was relatively high at 90%; therefore, it was difficult to obtain information on whether pirfenidone 
would be effective for patients who take lower doses in actual clinical settings.
A Japanese phase III clinical trial has shown that patients taking 1200 mg/day pirfenidone presented a similar 
efficacy in reducing FVC decline as patients taking 1800 mg/day  pirfenidone8. Therefore, we evaluated whether 
a lower dose (< 1200 mg/day) of pirfenidone would be as effective as a dose higher than 1200 mg pirfenidone 
and found that the lower dose was similarly effective as the high dose compared with the control group. We 
additionally evaluated the efficacy of pirfenidone at a dose of less than 1000 mg and found that it has a significant 
effect in reducing FVC decline (Supplementary Fig. 3). Unlike previous studies that evaluated medication dose as 
daily dose administered most frequently during the treatment  period13,16,17, in the present study, the medication 





























































































Figure 1.  (a) Distribution of pirfenidone dose (mg/day). (b–d) Scatter plot showing the relationship among 
age, body mass index, body surface area, and pirfenidone dose. Age and pirfenidone dose were negatively 
correlated (Pearson’s correlation efficiency, σ = − 0.302, p < 0.001). Body mass index, body surface area, and 
pirfenidone dose were positively correlated (Pearson’s correlation efficiency, σ = 0.201, p = 0.017; Pearson’s 
correlation efficiency, σ = 0.359, p < 0.001, respectively).
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dose was analyzed using the average dose that the patients took during the treatment period, considering actual 
clinical settings in which the dose is reduced and re-increased according to patient’s conditions and AEs. We 
believe that using the average dose to evaluate the efficacy is more reasonable than using the most frequently 
administered dose, which is a strength of this study.
We also evaluated the efficacy of pirfenidone according to the BSA-adjusted dose based on the mean value 
of 665.0 mg/m2 and revealed that the high-dose and low-dose groups showed a similar reduced FVC decline 
trend. A previous retrospective study in Japan evaluated the efficacy of pirfenidone according to the BSA-
adjusted dose and reported that, based on the median value of BSA-adjusted pirfenidone dose in their study 
population (876 mg/m2), patients receiving a higher dose showed significantly lower annual decline FVC than 
those taking lower doses. The study suggested that pirfenidone dosing regimen based on the BSA-adjusted dose 
might be  useful17. However, the study population was too small (n = 23) to be generalized. Regarding dosing of 





































Overall P value = 0.021
Figure 2.  FVC changes according to pirfenidone dose. The FVC declined more significantly in the control 
group compared with the high-dose and low-dose groups (overall p = 0.021). There was no significant difference 
in FVC change between the low-dose and high-dose groups (p = 0.976). FVC Forced vital capacity.
Table 2.  Adverse events according to pirfenidone dose. Values are expressed as number (%). GERD 
gastroesophageal reflux disease.
Total (n = 142) Low-dose (n = 79) High-dose (n = 63) P value
Dyspepsia 55 (38.7%) 38 (48.1%) 17 (27.0%) 0.017
Anorexia 36 (25.4%) 28 (35.4%) 8 (12.7%) 0.004
Rash 36 (25.4%) 23 (29.1%) 13 (20.6%) 0.337
Fatigue 23(16.2%) 11 (13.9%) 12 (19.0%) 0.552
Photosensitivity 16 (11.3%) 8 (10.1%) 8 (12.7%) 0.830
Nausea 15 (10.6%) 14 (17.7%) 1 (1.6%) 0.005
Dizziness 10 (7.0%) 7 (8.9%) 3 (4.8%) 0.536
Weight loss 8 (5.6%) 5 (6.3%) 3 (4.8%) 0.971
GERD 8 (5.6%) 4 (5.1%) 4 (6.3%) 1.000
Liver enzyme elevation 8 (5.6%) 5 (6.3%) 3 (4.8%) 0.971
Diarrhea 5 (3.5%) 1 (1.3%) 4 (6.3%) 0.240
Insomnia 7 (4.9%) 6 (7.6%) 1 (1.6%) 0.210
Headache 4 (2.8%) 2 (2.5%) 2 (3.2%) 1.000
Constipation 1(0.7%) 0 (0.0%) 1 (1.6%) 0.909
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pirfenidone based on the BSA-adjusted dose, further studies are required to evaluate its usefulness in efficacy 
and treatment-related AEs.
Our study had some limitations. First, we used a retrospective nonrandomized design, which is associated 
with various biases and confounding factors. Second, approximately 60% of the patients who did not follow up 
or were transferred to other hospitals were excluded. This selection bias may have influenced the final result. 
Third, this study was conducted in Korea, and therefore, the results cannot be directly applied to European and 
North American populations that take pirfenidone 2400 mg as a full dose. Finally, the information on the plasma 
concentration of the metabolite of the drug was not available to confirm the dose-dependent effects.
In conclusion, the present study revealed that low-dose pirfenidone (< 1200 mg/day) is also effective in 
reducing FVC decline. Dose reduction may help patients to better control AEs, especially GI tract-related AEs. 
We expect that providing clear instructions to physicians for dose modification to control AEs and educating 
patients to continue the medication even at low doses can help reduce FVC decline based on our study result, 
that is, taking pirfenidone at low doses is also effective.
Methods
Patients. We retrospectively reviewed the medical records of patients with IPF who were treated in the Sev-
erance Hospital, a tertiary care university hospital in South Korea, between January 2013 and March 2018. The 
inclusion criteria were as follows: patients (1) diagnosed with IPF, (2) followed up for more than one year, and 
(3) who underwent pulmonary function test for more than two times. Eight hundred and twenty patients with 
IPF were identified, and among those patients, 317 were treated with pirfenidone at least once and 503 patients 
were not treated with pirfenidone. Five hundred and eighty-six patients were excluded for the following rea-
sons (Fig. 3): follow-up loss (n = 401), incomplete pulmonary function test results (n = 30), lung transplantation 
(n = 113), and had taken pirfenidone for less than 6 months (n = 42). Finally, 142 patients who were treated with 
pirfenidone for more than 6 months and 92 patients who were not treated with pirfenidone were included in the 
study. This study was approved by the Institutional Review Board and Ethics Committee of Severance Hospital 
(IRB number: 4-2018-0435). All methods were performed in accordance with the Declaration of Helsinki. Writ-
ten informed consent was waived as the nature of retrospective study by IRB.
Definitions. Idiopathic pulmonary fibrosis was diagnosed via a multidisciplinary approach involving pul-
monologists as well as radiologists and pathologists specializing in chest diseases, in accordance with the diag-
nostic criteria set by the International Consensus Statement of the American Thoracic Society and European 
Respiratory Society in  20113. The gender–age–physiology (GAP) index was applied to assess the severity of 
IPF. The GAP index was calculated using gender (0–1 point), age (0–2 points), FVC (0–2 points), and diffusing 
capacity of the lungs for carbon monoxide  (DLCO; 0–3 points), and categorized into the following three stages: 
I (0–3 points), II (4–5 points), and III (6–8 points)18. Acute exacerbation of IPF (AE-IPF) was defined as acute, 
clinically significant respiratory deterioration characterized by evidence of new widespread alveolar abnormal-
ity; this meets the diagnostic criteria proposed by Collard et al.19.
Pirfenidone dose. Pirfenidone was initially prescribed at 600 mg/day dose, and the dose was increased 
every 1–2 weeks until the total dose reached 1800 mg/day, unless the patients experienced severe adverse event 
63 High-dose 
group (≥1200 mg/d)
503 patients not treated with pirfenidone
820 patients with 
IPF 
317 patients treated with pirfenidone
75 lost to follow-up, transfer to another 
hospital
38 lung transplantation
20 lack of PFT data
42 treatment period <6 months
142 Pirfenidone-treated group
326 lost to follow-up, transfer to another 
hospital
75 lung transplantation
10 lack of PFT data
92 Control group 
79 Low-dose group
(<1200 mg/d)
Figure 3.  Patient recruitment flow chart. IPF idiopathic pulmonary fibrosis, PFT pulmonary function test.
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(AE) and therefore could not continue pirfenidone. Studies have reported the gastrointestinal (GI) tract-related 
(e.g., nausea, dyspepsia, and diarrhea) and skin-related (e.g., photosensitivity and rash) AEs occur at a high 
 frequency5,11,12,20. These AEs can be alleviated by adjuvant treatments such as proton pump inhibitors, broad-
spectrum sunscreen or topical steroids, and dose reduction or  interruption20. For these reasons, it is often 
observed that dose reduction or interruption is necessary, depending on the severity of the AE, rather than 
maintaining a constant dose in actual clinical practice. Therefore, in the present study, we defined the dose of 
pirfenidone per day as “total amount of pirfenidone prescribed from the initiation of the drug divided by the 
observation period,” which represents the average dose the patients took during the treatment period. Addition-
ally, to evaluate the efficacy of pirfenidone dose adjusted according to the body size, the average dose of pirfeni-
done was divided by body surface area (BSA), which was calculated using the Du Bois  formula21.
Statistical analysis. The changes in FVC from the baseline to 12 months were assessed using the linear 
mixed model with Bonferroni correction. Age, sex, height, and weight that affect the FVC value were adjusted in 
the linear mixed model. Continuous variables were analyzed using the analysis of variance and Kruskal–Wallis 
test. Categorical variables were analyzed using chi-squared distribution and Fisher’s exact tests. In all cases, the 
results with a p value of < 0.05 were considered statistically significant. All statistical analyses were performed 
using SAS program, version 9.4 (SAS Institute, Cary, NC, USA).
Ethics approval and consent to participate. This study was approved by the Institutional Review 
Board and Ethics Committee of Severance Hospital (IRB number: 4-2018-0435). Written informed consent was 
waived as the nature of retrospective study by IRB.
Data availability
The datasets used and analyzed in the current study are available from the corresponding author on reasonable 
request.
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